Sun Trust states that Vascepa may be attractive to BP suitors. I wonder what AMRN management has in mind if a friendly bid came their way. My belief is that Vascepa has the potential to be a $10 billion in revenue type drug. ( 5 million patients to do that.) My opinion is that BP would get us there faster. Would BP ever pay an amount large enough based upon the potential? If I controlled a BP I would buy as much stock as possible in order to make certain noone else could outbid me if I wanted to make a move. Given what may be at stake for BP, I cannot understand why no BP has a position in this.
News 
Market Data 
Discover 
